The Food and Drug Administration is shifting funds during the government shutdown to prioritize drug safety surveillance over pre-market drug review work, the agency’s commissioner has announced
“We’re making decisions across our portfolio to focus #FDA resources to key consumer protection functions. One action we’ll be taking is to re-allocate user fee money from certain pre-market drug review work to post market drug safety surveillance,” Dr. Scott Gottlieb said Tuesday in a tweet.
